Emory University School of Medicine has appointed Carlton Dampier, MD, a national leader in the study and treatment of sickle cell disease, as medical director of its Office for Clinical Research. Dampier also will be a professor in the Department of Pediatrics and assistant dean for clinical research in the School of Medicine.
As a member of the Atlanta Clinical and Translational Science Institute, led by Emory University along with partners Morehouse School of Medicine, Georgia Institute of Technology and Children's Healthcare of Atlanta, Dampier will direct the Ethics, Regulatory Knowledge and Support Program.
"We are very fortunate to have Carlton Dampier as medical director of our Clinical Trials Office," says Thomas J. Lawley, MD, dean of EEmory University School of Medicine. "He has played a major leadership role in the development of sickle cell disease treatment and clinical research programs, and he brings experience to our expanding clinical trials enterprise and clinical trials partnerships."
A graduate of the Illinois Institute of Technology, Dampier received his medical degree from the Pritzker School of Medicine at the University of Chicago. He completed his residency and fellowships at Wyler Children's Hospital of the University of Chicago Medical Center.
Before joining Emory, Dampier was professor of pediatrics and associate chair for research at Drexel University College of Medicine and medical director of the Marian Anderson Sickle Cell Anemia Care and Research Center. He was director of clinical research, chief of hematology and medical director of the Advanced Blood Conservation Program at St. Christopher's Hospital for Children in Philadelphia.
He previously was a faculty member in pediatrics at the University of Chicago Pritzker School of Medicine, Temple University School of Medicine and MCP-Hahnemann School of Medicine. He is board certified in pediatrics and pediatric hematology-oncology, and is certified as a clinical investigator by the Association of Clinical Research Professionals and by the Academy of Pharmaceutical Physicians and Investigators.
An active clinical researcher, Dampier has been funded for over 15 years by the National Heart, Lung, and Blood Institute of the National Institutes of Health for his studies of patient reported outcomes, such as pain and quality of life in children with sickle cell disease. He has served on numerous leadership positions in the National Sickle Cell Disease Program, including the National Institutes of Health’s Comprehensive Sickle Cell Program and the Sickle Cell Disease Clinical Research Network, which he currently chairs.
As an accomplished educator, Dampier has lectured extensively on the assessment and management of pain in children, and in the use of alternatives to blood transfusion in children.